Overview

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours

Status:
Not yet recruiting

Trial end date:
2025-06-02

Target enrollment:

Participant gender:

Summary

TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Daiichi Sankyo, Inc.

Treatments:

Bevacizumab
Capecitabine
Carboplatin
Durvalumab
Fluorouracil
Leucovorin
Nivolumab